Skip to main content

Table 1 Cohort characteristics

From: The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas

Age

mean 49.6 years (range 19–85)

Variable

N

Sex

 Male

45

 Female

52

WHO grade

 I

4

 II

11

 III

15

 IV

70

Histotype

 Astrocytic

91

 Oligodendroglial

9

IDH1 status

 Wild-type

66

 Mutant

34

MGMT status

 Methylated

45

 Unmethylated

49

 Unknown

6

Recurrent

 Yes

38

 No

62

TMZ treatment

 Pre

67

 Post

33

Hypermutated

 

 Yes

9

 No

91

TOTAL

100

  1. N = 100 tumors from 96 patients (two females each had two tumors in this cohort, and one male had three tumors). See Additional file 1: Table S1 for further information on each tumor. TMZ temozolomide
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us